COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients (COPANA)
Sponsor: Amgen
A observational or N/A phase clinical study on Dyslipidemias and HIV Seropositivity, this trial is completed. The trial is conducted by Amgen and has accumulated 13 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2024 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Feb 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Sep 2020 — Nov 2020 [monthly]
Completed
-
Aug 2019 — Sep 2020 [monthly]
Completed
-
Jun 2018 — Aug 2019 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jun 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Franck Boccara
- Institut National de la Santé Et de la Recherche Médicale, France
- National Agency for Research on AIDS and Viral Hepatitis (ANRS)
For direct contact, visit the study record on ClinicalTrials.gov .